Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

Federal Court in Canada Upholds Pfizer's Norvasc Patent; Decision Prevents Launch of Generic Amlodipine Besylate Product by Pharmascience until 2010


Print article Print article
Refer this article Refer to a friend
© Business Wire 2008
2008-04-17 23:43:29 -

www.pfizer.com - Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued an order prohibiting regulatory approval of Pharmascience's proposed product in Canada until Pfizer's amlodipine besylate patent - Canadian Patent No. 1,321,393 - expires in August 2010. Pharmascience may appeal the
decision to the Federal Court of Appeal of Canada.

The company noted that legal challenges to this patent in Canada by other generic manufacturers are still pending.

Pfizer Inc
Chris Loder, 212-733-7897




Disclaimer: (c) 2007 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.


Terms & Conditions | About us | Contact PR-inside.com